ANKL
MCID: NTR003
MIFTS: 41

Natural Killer Cell Leukemia (ANKL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Natural Killer Cell Leukemia

MalaCards integrated aliases for Natural Killer Cell Leukemia:

Name: Natural Killer Cell Leukemia 12 15
Aggressive Nk-Cell Leukemia 12 59
Leukemia, Natural Killer Cell Large Granular Lymphocytic 73
Large Granular Lymphocyte Leukemia, Nk-Cell Type 12
Nk-Cell Large Granular Lymphocyte Leukemia 59
Aggressive Natural Killer Cell Leukemia 53
Aggressive Natural Killer-Cell Leukemia 73
Leukemia, Large Granular Lymphocytic 73
Aggressive Nk Cell Leukemia 53
Aggressive Nk-Cell Lymphoma 59
Abnormality of the Ankles 29
Nk-Cell Lgl Leukemia 59
Ankcl 59
Ankl 53

Characteristics:

Orphanet epidemiological data:

59
aggressive nk-cell leukemia
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:1035
ICD10 33 C94.8
NCIt 50 C8647
Orphanet 59 ORPHA86873
UMLS via Orphanet 74 C1522378 C1292777
ICD10 via Orphanet 34 C94.7

Summaries for Natural Killer Cell Leukemia

MalaCards based summary : Natural Killer Cell Leukemia, also known as aggressive nk-cell leukemia, is related to composite lymphoma and panniculitis, and has symptoms including fever An important gene associated with Natural Killer Cell Leukemia is TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein), and among its related pathways/superpathways are NF-kappaB Signaling and Hematopoietic cell lineage. The drugs leucovorin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include nk cells, t cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Natural Killer Cell Leukemia

Diseases related to Natural Killer Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 517)
# Related Disease Score Top Affiliating Genes
1 composite lymphoma 30.2 TIA1 GZMB
2 panniculitis 29.7 TIA1 NCAM1 GZMB
3 lichen sclerosus et atrophicus 29.5 TIA1 GZMB
4 subcutaneous panniculitis-like t-cell lymphoma 29.2 TIA1 NCAM1 GZMB
5 peripheral t-cell lymphoma 29.2 TIA1 NCAM1 GZMB
6 tenosynovitis of foot and ankle 12.1
7 hemarthrosis 11.7
8 arthropathy 11.7
9 pigmented villonodular synovitis 11.3
10 tarsal tunnel syndrome 11.3
11 hemophilia 11.3
12 mesomelic dysplasia, kantaputra type 11.2
13 foot drop 11.2
14 tendinitis 11.1
15 exostosis 11.1
16 septic arthritis 11.1
17 gout 11.1
18 osteonecrosis 11.1
19 fibular hemimelia 11.1
20 navicular bone, accessory 11.1
21 buschke-ollendorff syndrome 11.1
22 psoriatic arthritis 11.1
23 lichen planus 11.1
24 polymyositis 11.1
25 myopathy, distal, 1 11.1
26 ulcer of lower limbs 11.0
27 behcet's syndrome arthropathy 11.0
28 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 11.0
29 distal myopathy with vocal cord weakness 11.0
30 arthrogryposis, distal, type 9 10.9
31 hand-foot-genital syndrome 10.9
32 larsen syndrome 10.9
33 bethlem myopathy 1 10.9
34 tarsal-carpal coalition syndrome 10.9
35 anemia, sideroblastic, and spinocerebellar ataxia 10.9
36 epiphyseal dysplasia, multiple, 2 10.9
37 epidermolysis bullosa simplex, autosomal recessive 2 10.9
38 poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis 10.9
39 spondyloepimetaphyseal dysplasia, di rocco type 10.9
40 ehlers-danlos syndrome, classic-like, 2 10.9
41 patellar tendinitis 10.9
42 emery-dreifuss muscular dystrophy 10.9
43 decubitus ulcer 10.9
44 childhood-onset nemaline myopathy 10.9
45 harding ataxia 10.9
46 welander distal myopathy, swedish type 10.9
47 adie pupil 10.8
48 amyloidosis, primary localized cutaneous, 1 10.8
49 atrial standstill 1 10.8
50 epiphyseal dysplasia, multiple, 1 10.8

Graphical network of the top 20 diseases related to Natural Killer Cell Leukemia:



Diseases related to Natural Killer Cell Leukemia

Symptoms & Phenotypes for Natural Killer Cell Leukemia

UMLS symptoms related to Natural Killer Cell Leukemia:


fever

GenomeRNAi Phenotypes related to Natural Killer Cell Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.53 CD2 GZMB MPO TIA1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.53 CD2 GZMB MPO TIA1

Drugs & Therapeutics for Natural Killer Cell Leukemia

Drugs for Natural Killer Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 1, Phase 2,Early Phase 1 58-05-9 6006 143
2
Hydroxocobalamin Approved Phase 1, Phase 2 13422-51-0 11953898 44475014
3
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
4
Methylcobalamin Approved, Experimental, Investigational Phase 1, Phase 2 13422-55-4
5
Cyanocobalamin Approved, Nutraceutical Phase 1, Phase 2 68-19-9 44176380
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2,Early Phase 1 59-30-3 6037
7
Cobalamin Experimental Phase 1, Phase 2 13408-78-1 6438156
8 Antiviral Agents Phase 1, Phase 2
9 Micronutrients Phase 1, Phase 2
10 Vitamin B 12 Phase 1, Phase 2
11 Vitamin B9 Phase 1, Phase 2,Early Phase 1
12 Folic Acid Antagonists Phase 1, Phase 2,Early Phase 1
13 Vitamin B Complex Phase 1, Phase 2,Early Phase 1
14 Anti-Infective Agents Phase 1, Phase 2,Not Applicable
15 10-deazaaminopterin Phase 1, Phase 2
16 Hematinics Phase 1, Phase 2
17 Folate Phase 1, Phase 2,Early Phase 1
18 Antimetabolites Phase 1, Phase 2,Not Applicable,Early Phase 1
19 Immunologic Factors Phase 1, Phase 2,Not Applicable,Early Phase 1
20 Trace Elements Phase 1, Phase 2
21 Vitamin B12 Phase 1, Phase 2
22 Vitamins Phase 1, Phase 2
23 Antimetabolites, Antineoplastic Phase 1, Phase 2,Not Applicable,Early Phase 1
24 Immunosuppressive Agents Phase 1, Phase 2,Not Applicable,Early Phase 1
25
Sunitinib Approved, Investigational Phase 1 557795-19-4, 341031-54-7 5329102
26
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
27
Nelfinavir Approved Phase 1 159989-64-7 64143
28 Angiogenesis Inhibitors Phase 1
29 Angiogenesis Modulating Agents Phase 1
30
protease inhibitors Phase 1,Early Phase 1
31 Anti-HIV Agents Phase 1
32 HIV Protease Inhibitors Phase 1,Early Phase 1
33 Anti-Retroviral Agents Phase 1
34
Fludarabine Approved Not Applicable 75607-67-9, 21679-14-1 30751
35
Mycophenolic acid Approved Not Applicable 24280-93-1 446541
36
Miconazole Approved, Investigational, Vet_approved Not Applicable 22916-47-8 4189
37
Prednisone Approved, Vet_approved Early Phase 1 53-03-2 5865
38
Dexamethasone acetate Approved, Investigational, Vet_approved Early Phase 1 1177-87-3
39
Dexamethasone Approved, Investigational, Vet_approved Early Phase 1 50-02-2 5743
40
Methotrexate Approved Early Phase 1 59-05-2, 1959-05-2 126941
41
Mechlorethamine Approved, Investigational Early Phase 1 51-75-2 4033
42
Etoposide Approved Early Phase 1 33419-42-0 36462
43
Pegaspargase Approved, Investigational Early Phase 1 130167-69-0
44
Doxorubicin Approved, Investigational Early Phase 1 23214-92-8 31703
45
Pembrolizumab Approved Early Phase 1 1374853-91-4
46
Ifosfamide Approved Early Phase 1 3778-73-2 3690
47
Cyclophosphamide Approved, Investigational Early Phase 1 6055-19-2, 50-18-0 2907
48
Doxil Approved June 1999 Early Phase 1 31703
49 Antirheumatic Agents Not Applicable,Early Phase 1
50 Vidarabine Phosphate Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
2 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
3 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
4 Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer Completed NCT01164709 Phase 1 bortezomib;nelfinavir mesylate
5 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed NCT00112593 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil
6 INDUCTION CHEMO-IMMUNOTHERAPY FOLLOWED BY CONSOLIDATION WITH REDUCED TOXICITY CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANT IN ADVANCED STAGE MATURE NON-ANAPLASTIC T-CELL OR NK LYMPHOMA/LEUKEMIA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS Not yet recruiting NCT03719105 Early Phase 1 Methotrexate, ifosfamide, dexamethasone, etoposide, pegasparagase,;pralatraxate, cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin
7 Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection Not yet recruiting NCT03491605

Search NIH Clinical Center for Natural Killer Cell Leukemia

Genetic Tests for Natural Killer Cell Leukemia

Genetic tests related to Natural Killer Cell Leukemia:

# Genetic test Affiliating Genes
1 Abnormality of the Ankles 29

Anatomical Context for Natural Killer Cell Leukemia

MalaCards organs/tissues related to Natural Killer Cell Leukemia:

41
Nk Cells, T Cells, Bone, Myeloid, Brain, Kidney, Heart

Publications for Natural Killer Cell Leukemia

Articles related to Natural Killer Cell Leukemia:

(show top 50) (show all 96)
# Title Authors Year
1
Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia. ( 29889803 )
2018
2
Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. ( 29148541 )
2018
3
Combination statin and chemotherapy inhibits proliferation and cytotoxicity of an aggressive natural killer cell leukemia. ( 30116531 )
2018
4
Aggressive NK-Cell Leukemia. ( 30364049 )
2018
5
Aggressive natural killer cell leukemia: a case report. ( 29263706 )
2017
6
EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features. ( 27631517 )
2017
7
Achievement of disease control with donor-derived EB virus-specific cytotoxic T cells after allogeneic peripheral blood stem cell transplantation for aggressive NK-cell leukemia. ( 27830541 )
2017
8
Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. ( 28161608 )
2017
9
EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution. ( 28548121 )
2017
10
CD56-Negative Aggressive NK Cell Leukemia Relapsing as Multiple Cranial Nerve Palsies: Case Report and Literature Review. ( 29163992 )
2017
11
Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. ( 29263371 )
2017
12
Aggressive natural killer cell leukemia or extranodal NK/T cell lymphoma? a case with nasal involvement. ( 28623913 )
2017
13
Aggressive natural killer cell leukemia associated with hemophagocytic lymphohistiocytosis ( 28829111 )
2016
14
EBV-associated aggressive natural killer cell leukemia. ( 28092886 )
2016
15
Clinicopathologic Characterization of Aggressive Natural Killer Cell Leukemia Involving Different Tissue Sites. ( 26975038 )
2016
16
A relapsed aggressive NK-cell leukemia with CNS involvement diagnosed by cerebrospinal fluid examination. ( 26890009 )
2016
17
Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis. ( 27483437 )
2016
18
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. ( 27566560 )
2016
19
L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. ( 27091029 )
2016
20
Aggressive natural killer cell leukemia associated with hemophagocytic lymphohistiocytosis. ( 28829754 )
2016
21
Aggressive NK-cell leukemia in a 69 years old Caucasian woman: a case report. ( 26682116 )
2015
22
Long complete remission achieved with the combination therapy of Cisplatin and gemcitabine in a patient with aggressive natural killer cell leukemia. ( 25694835 )
2015
23
Spontaneous Hepatic Rupture Associated With Epstein-Barr Virus Negative Aggressive Natural Killer Cell Leukemia. ( 29147405 )
2014
24
18F-FDG PET for diagnosis and response assessment for aggressive NK cell leukemia. ( 23751830 )
2014
25
Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. ( 23772641 )
2014
26
Six cases of aggressive natural killer-cell leukemia in a Chinese population. ( 25031771 )
2014
27
Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia. ( 24524877 )
2014
28
Aggressive natural killer-cell leukemia: classical presentation of a rare disease. ( 25118753 )
2014
29
Rare aggressive natural killer cell leukemia presented with bone marrow fibrosis - a diagnostic challenge. ( 25126488 )
2014
30
A probable identical Epstein-Barr virus clone-positive composite lymphoma with aggressive natural killer-cell leukemia and cytotoxic T-cell lymphoma. ( 24427365 )
2013
31
Successful disease control with L-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure. ( 22891745 )
2013
32
Adult aggressive natural killer cell leukemia. ( 23241562 )
2013
33
Favorable outcome in a child with EBV-negative aggressive NK cell leukemia. ( 23550023 )
2013
34
Aggressive natural killer-cell leukemia with jaundice and spontaneous splenic rupture: a case report and review of the literature. ( 23510456 )
2013
35
Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. ( 23181473 )
2013
36
Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. ( 22360679 )
2012
37
Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication. ( 23037625 )
2012
38
Ocular palsy associated with aggressive NK-cell leukemia. ( 21607654 )
2011
39
The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia. ( 21628857 )
2011
40
F-18 FDG PET/CT findings of aggressive NK-cell leukemia. ( 21892052 )
2011
41
Treatment of Aggressive NK-Cell Leukemia: A Case Report and Review of the Literature. ( 22937312 )
2011
42
Collapsing glomerulopathy associated with natural killer cell leukemia: a case report and review of the literature. ( 21908087 )
2011
43
Sustained CR of refractory aggressive natural killer cell leukemia following unrelated cord blood transplantation. ( 20676148 )
2010
44
Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. ( 19850638 )
2010
45
Successful allogeneic hematopoietic stem cell transplantation for aggressive NK cell leukemia. ( 20823655 )
2010
46
Long term survival in aggressive NK cell leukemia. ( 21048272 )
2010
47
Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. ( 21116747 )
2010
48
Epstein-Barr virus-associated proliferative disorder presenting as Hodgkin's lymphoma and developing as aggressive natural killer-cell leukemia 19 years later: a case report of composite lymphoma. ( 19269751 )
2009
49
Frequent CD7 antigen loss in aggressive natural killer-cell leukemia: a useful diagnostic marker. ( 20046078 )
2009
50
A case of natural killer cell leukemia misdiagnosed as tuberculous lymphadenopathy. ( 19571615 )
2009

Variations for Natural Killer Cell Leukemia

Expression for Natural Killer Cell Leukemia

Search GEO for disease gene expression data for Natural Killer Cell Leukemia.

Pathways for Natural Killer Cell Leukemia

Pathways related to Natural Killer Cell Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 CD2 GZMB MPO NCAM1
2 11.24 CD2 IL7
3 11.03 GZMB IL7 NCAM1
4 10.99 CD2 IL7 MPO NCAM1

GO Terms for Natural Killer Cell Leukemia

Sources for Natural Killer Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....